NEU 3.32% $20.52 neuren pharmaceuticals limited

intrrepid-phase 111 trial., page-2

  1. 10,009 Posts.
    Should have read further, next line says Phase 2 trial desigened to give definitive answers to several approvable endpoints.

    So results from Phase 2 trials will give all the answers we need. And from recent updates all is going well. Not only is NEU looking cheap, well funded, and close to major results, it is looking likely to make it to market.

    PoS
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.